X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Pharmanovia expands its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from Sanofi, including Frisium (clobazam), Gardenal (phenobarbital), Tercian (cyamemazine), Stemetil, Sentil, Urbanyl, Urbanil, Urbanol, Urbadan, Noiafren and Castilium.
Lead Product(s): Clobazam
Therapeutic Area: Psychiatry/Psychology Product Name: Frisium
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pharmanovia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment September 18, 2023
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Under the partnership, Cipla will be responsible for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range, including Frisium (clobazam), a brand in the anti-epileptic medication category, in India.
Lead Product(s): Clobazam
Therapeutic Area: Neurology Product Name: Frisium
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 27, 2024
Details:
SYMPAZAN (clobazam) is the first and only FDA-approved oral film formulation of clobazam, a benzodiazepine approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.
Lead Product(s): Clobazam
Therapeutic Area: Neurology Product Name: Sympazan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: LGS Foundation
Deal Size: $0.1 million Upfront Cash: Undisclosed
Deal Type: Partnership January 17, 2023
Details:
Sympazan® (clobazam), oral film developed with PharmFilm® technology, is a prescription medicine used to treat seizures associated with Lennox-Gastaut Syndrome in people 2 years of age or older. Clobazam positive allosteric modulator of GABA receptor.
Lead Product(s): Clobazam
Therapeutic Area: Neurology Product Name: Sympazan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Under the terms of the definitive agreement, Aquestive exclusively licensed the product’s intellectual property to Assertio for an upfront payment. Aquestive also entered into a long-term supply agreement with Assertio for Sympazan (clobazam) oral film.
Lead Product(s): Clobazam
Therapeutic Area: Neurology Product Name: Sympazan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Assertio Therapeutics
Deal Size: Undisclosed Upfront Cash: $9.0 million
Deal Type: Licensing Agreement October 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
